Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Aytu Biopharma (AYTU) Receivables - Net (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Receivables - Net for 11 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 21.73% to $30.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.9 million, a 21.73% increase, with the full-year FY2025 number at $31.2 million, up 32.43% from a year prior.
  • Receivables - Net was $30.9 million for Q4 2025 at Aytu Biopharma, down from $33.2 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $35.8 million in Q1 2025 to a low of $21.6 million in Q3 2021.
  • A 5-year average of $28.3 million and a median of $29.4 million in 2023 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: skyrocketed 438.35% in 2021, then decreased 25.83% in 2024.
  • Aytu Biopharma's Receivables - Net stood at $23.0 million in 2021, then increased by 10.92% to $25.5 million in 2022, then increased by 15.29% to $29.4 million in 2023, then dropped by 13.6% to $25.4 million in 2024, then rose by 21.73% to $30.9 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Receivables - Net are $30.9 million (Q4 2025), $33.2 million (Q3 2025), and $31.2 million (Q2 2025).